GlaxoSmithKline Pharmaceuticals (BOM:500660) Cyclically Adjusted Revenue per Share: ₹234.66 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500660 GlaxoSmithKline Pharmaceuticals Ltd BOM:500660
74 GF Score
Price ₹2,689.10
GF Value ₹2,721.88
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share?

GlaxoSmithKline Pharmaceuticals BOM:500660 +0.92% 74 Cyclically Adjusted Revenue per Share is ₹234.66 as of Jun. 2026. GuruFocus rates BOM:500660 with a GF Score™ of 74/100 and a GF Value™ of ₹2,721.88 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GlaxoSmithKline Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹55.393. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹234.66 for the trailing ten years ended in Jun. 2026.

During the past 12 months, GlaxoSmithKline Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 4.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-16), GlaxoSmithKline Pharmaceuticals's current stock price is ₹2689.10. GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹234.66. GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 11.46.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlaxoSmithKline Pharmaceuticals was 15.47. The lowest was 8.72. And the median was 11.34.


GlaxoSmithKline Pharmaceuticals  (BOM:500660) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2689.10/234.66
=11.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlaxoSmithKline Pharmaceuticals was 15.47. The lowest was 8.72. And the median was 11.34.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 223.49 232.41

GlaxoSmithKline Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 225.39 229.05 230.93 232.41 234.66

BOM:500660 vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:500660
74GF Score
GlaxoSmithKline Pharmaceuticals Ltd BOM:500660
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlaxoSmithKline Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=55.393/167.3573*167.3573
=55.393

Current CPI (Jun. 2026) = 167.3573.

GlaxoSmithKline Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 0.000 83.774 0.000
201312 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201706 34.418 107.109 53.778
201803 0.000 109.786 0.000
201806 43.397 111.317 65.245
201809 48.171 115.142 70.016
201812 48.721 115.142 70.815
201903 42.549 118.202 60.243
201906 46.498 120.880 64.376
201909 52.070 123.175 70.747
201912 45.962 126.235 60.934
202003 44.235 124.705 59.364
202006 38.273 127.000 50.435
202009 51.860 130.118 66.702
202012 46.750 130.889 59.775
202103 42.370 131.771 53.813
202106 42.421 134.084 52.948
202109 55.158 135.847 67.952
202112 48.190 138.161 58.374
202203 46.962 138.822 56.615
202206 43.976 142.347 51.702
202209 54.134 144.661 62.627
202212 47.340 145.763 54.353
202303 44.999 146.865 51.278
202306 44.980 150.280 50.091
202309 56.493 151.492 62.409
202312 47.555 152.924 52.043
202403 54.147 153.035 59.215
202406 48.076 155.789 51.646
202409 59.686 157.882 63.268
202412 56.045 158.323 59.243
202503 57.527 157.552 61.107
202506 47.522 159.755 49.783
202509 57.847 162.289 59.653
202512 61.464 163.281 62.999
202603 58.745 164.272 59.848
202606 55.393 167.357 55.393

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹234.66 mean?
GlaxoSmithKline Pharmaceuticals (BOM:500660) has a Cyclically Adjusted Revenue per Share of ₹234.66 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
GlaxoSmithKline Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹234.66. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹234.66 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹234.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (BOM:500660) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,721.88, compared to a current price of ₹2,689.10 — trading 1.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹234.66. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (BOM:500660), the current Cyclically Adjusted Revenue per Share is ₹234.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (BOM:500660) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,689.10 is trading 1.2% below its estimated GF Value™ of ₹2,721.88. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for BOM:500660:

  • Cyclically Adjusted Revenue per Share: ₹234.66
  • GF Value™: ₹2,721.88 vs. price of ₹2,689.10 (1.2% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the BOM:500660 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges GLAXO:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
74GF Score

Get the complete analysis for BOM:500660

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,689.10
Price
₹2,721.88
GF Value